Results 21 to 30 of about 6,010 (246)

Identification of a promising new class of latency reversing agents

Journal of Virus Eradication, 2017
A. Gramatica, W. Greene, R. Schwarzer, M. Montano, T. Packard, E. Herzig, Warner Greene   +6 more
doaj   +2 more sources

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal

Journal of Virus Eradication, 2016
T.M. Mota, G. Khoury, J.C. Jacobson, H.K. Lu, F. Wightman, d.e.r. Sluis, J.L. Anderson, P.U. Cameron, S.R. Lewin, D.F.J. Purcell, R.M. Van   +10 more
doaj   +2 more sources

Diversity of small molecule HIV‐1 latency reversing agents identified in low‐ and high‐throughput small molecule screens [PDF]

Medicinal Research Reviews, 2020
Pargol Hashemi, Ivan Sadowski
exaly   +2 more sources

G-quadruplex ligands targeting telomeres do not inhibit HIV promoter activity and cooperate with latency reversing agents in killing latently infected cells [PDF]

Cell Cycle, 2020
Dorota Piekna-Przybylska, Robert A Bambara, Sanjay B Maggirwar   +2 more
exaly   +2 more sources

Optimisation of Smac mimetics as HIV-1 latency reversing agents

Journal of Virus Eradication, 2019
L. Pache, P. Teriete, M.D. Marsden, A.M. Spivak, D. Heimann, A.J. Portillo, V. Planelles, J.A. Zack, N.D.P. Cosford, S.K. Chanda   +9 more
doaj   +2 more sources

Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. [PDF]

AIDS, 2020
Objective: While latently HIV-infected cells have been described in the blood, it is unclear whether a similar inducible reservoir exists in the gut, where most HIV-infected cells reside. Tissue-specific environments may contribute to differences in the mechanisms that govern latent HIV infection and amenability to reactivation.
Telwatte S, Kim P, Chen TH, Milush JM, Somsouk M, Deeks SG, Hunt PW, Wong JK, Yukl SA.   +8 more
europepmc   +6 more sources

Dual TLR2 and TLR7 agonists as HIV latency-reversing agents. [PDF]

JCI Insight, 2018
The presence of a reservoir of latently infected cells in HIV-infected patients is a major barrier towards finding a cure. One active cure strategy is to find latency-reversing agents that induce viral reactivation, thus leading to immune cell recognition and elimination of latently infected cells, known as the shock-and-kill strategy.
Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A.   +10 more
europepmc   +4 more sources

Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA. [PDF]

Biol Open, 2020
Infection of HIV-1 remains incurable because long-lived, latently-infected cells persist during prolonged antiretroviral therapy. Attempts to pharmacologically reactivate and purge the latent reservoir with latency reactivating agents (LRAs) such as protein kinase C (PKC) agonists (e.g. ingenol A) or histone deacetylase (HDAC) inhibitors (e.g.
Taylor JP, Armitage LH, Aldridge DL, Cash MN, Wallet MA.   +4 more
europepmc   +5 more sources

Novel Triazolopyridine-Based BRD4 Inhibitors as Potent HIV-1 Latency Reversing Agents [PDF]

ACS Medicinal Chemistry Letters
Zhiyu Li, Ren-Rong Tian, Liu-Meng Yang   +2 more
exaly   +2 more sources

Novel Latency Reversal Agents for HIV-1 Cure. [PDF]

Annu Rev Med, 2018
Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate ...
Spivak AM, Planelles V.
europepmc   +4 more sources